ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial

T790米 奥西默替尼 贝伐单抗 医学 肿瘤科 内科学 表皮生长因子受体 癌症 埃罗替尼 化疗 吉非替尼
作者
Ross A. Soo,Urania Dafni,Ji‐Youn Han,Byoung Chul Cho,Ernest Nadal,Chong Ming Yeo,Enric Carcereny,Javier de Castro,M.Á. Sala González,Linda Coate,Mariano Provencio,Christian Britschgi,Patrick Vagenknecht,Georgia Dimopoulou,Roswitha Kammler,Stephen P. Finn,Solange Peters,Rolf A. Stahel,for the ETOP 10-16 BOOSTER Collaborators
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:30 (22): 5180-5191 被引量:1
标识
DOI:10.1158/1078-0432.ccr-24-0932
摘要

PURPOSE: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. EXPERIMENTAL DESIGN: Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described. RESULTS: A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively. CONCLUSIONS: The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhang发布了新的文献求助10
刚刚
1秒前
dd36发布了新的文献求助10
2秒前
炒米粉完成签到,获得积分0
2秒前
罗二狗发布了新的文献求助10
2秒前
秋风的应助被欣灵采纳,获得25
2秒前
NexusExplorer的应助被开心德地采纳,获得10
4秒前
罗二狗发布了新的文献求助10
4秒前
5秒前
罗二狗发布了新的文献求助10
6秒前
6秒前
认真绾绾完成签到,获得积分10
6秒前
6秒前
搜集达人的应助被开心德地采纳,获得10
7秒前
科研通AI65的应助被zhang采纳,获得10
7秒前
罗二狗发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
7秒前
搞怪灯泡发布了新的文献求助50
7秒前
8秒前
Liu Luke关注了科研通微信公众号
8秒前
9秒前
Li完成签到,获得积分10
9秒前
杨德凯完成签到,获得积分20
9秒前
9秒前
深情安青的应助被开心德地采纳,获得10
10秒前
Hanniewei发布了新的文献求助50
10秒前
陈昭琼完成签到 ,获得积分10
10秒前
周思发布了新的文献求助10
10秒前
dimension完成签到,获得积分10
11秒前
坚定寒松发布了新的文献求助10
11秒前
11秒前
自觉德天完成签到 ,获得积分10
12秒前
罗二狗发布了新的文献求助10
12秒前
7Wen发布了新的文献求助10
12秒前
12秒前
罗二狗发布了新的文献求助10
12秒前
Lucas的应助被要减肥的青荷采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509